Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2965-2974

  Nishio, H ^a   Yaguchi, T ^a   Sugiyama, J ^a   Sumimoto, H ^a   Umezawa, K ^a   Iwata, T ^a   Susumu, N ^a   Fujii, T ^a   Kawamura, N ^a   Kobayashi, A ^a   Park, J ^a   Aoki, D ^a   Kawakami, Y ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

IL 6; IL 8; Immunosuppression; NF B; Ovarian cancer

Indexed keywords

ARGINASE; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER IMMUNOTHERAPY; CANCER MODEL; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFANT; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOTTING; SUPERNATANT; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR XENOGRAFT;

ADOPTIVE TRANSFER; ANIMALS; ARGINASE; BENZAMIDES; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYCLOHEXANONES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-6; INTERLEUKIN-8; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84902551922     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.251     Document Type: Article

References (42)

1. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, De Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD (2011) IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 17(8): 2538-2548
2. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC (2010) Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116(13): 3276-3284
3. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K (2002) Inhibition of tumor necrosis factor-Alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 277(27): 24625-24630. (Pubitemid 34951991
4. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy?. Hopes and pitfalls. Nat Rev Drug Discov 8(1): 33-40
5. Ben-Baruch A (2012) The tumor-promoting flow of cells into, within and out of the tumor site: Regulation by the inflammatory axis of TNFalpha and chemokines. Cancer Microenviron 5(2): 151-164
6. Coward J, Kulbe H, Chakravarty P, Leader DA, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth JA, Vermeulin J, Singh N, Avril NE, Cummings J, Rexhepaj E, Jirstrom K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17(18): 6083-6096
7. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR (2010) Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 9(2): 260-268
8. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E (2010) Enrichment of Foxp3 CD4 regulatory T cells in migrated T cells to IL-6-And IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185(11): 6734-6740
9. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra-And peritumoral immune infiltrates. Cancer Res 71(17): 5601-5605
10. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, Spranger S (2013) Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 25(2): 268-276
11. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DS (2008) Human high molecular weight-melanoma- Associated antigen: Utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 14(11): 3401-3407
12. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51(1): 15-36. (Pubitemid 32166444
13. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1): 11-19
14. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71(17): 5670-5677
15. Hamanishi J, Mandai M, Abiko K, Matsumura N, Baba T, Yoshioka Y, Kosaka K, Konishi I (2011) The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141(3): 338-347
16. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5): 646-674
17. He G, Karin M (2010) NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res 21(1): 159-168
18. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-Analysis. Gynecol Oncol 124(2): 192-198
19. Ivarsson K, Ekerydh A, Fyhr IM, Janson PO, Brannstrom M (2000) Upregulation of interleukin-8 and polarized epithelial expression of interleukin-8 receptor A in ovarian carcinomas. Acta Obstet Gynecol Scand 79(9): 777-784
20. Iwata-Kajihara T, Sumimoto H, Kawamura N, Ueda R, Takahashi T, Mizuguchi H, Miyagishi M, Takeda K, Kawakami Y (2011) Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors. J Immunol 187(1): 27-36
21. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441(7092): 431-436
22. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10): 749-759. (Pubitemid 41400849
23. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D, Khalifa A (2004) Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37(5): 363-369. (Pubitemid 38490454
24. Kawakami Y, Fujita T, Matsuzaki Y, Sakurai T, Tsukamoto M, Toda M, Sumimoto H (2004) Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95(10): 784-791. (Pubitemid 39545583
25. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van Der Zee AG, Melief CJ, van Der Burg SH, Daemen T, Nijman HW (2009) Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 125(9): 2104-2113
26. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K (2005) Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11(3): 1287-1293. (Pubitemid 40175782
27. Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K, Umezawa K (2010) Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun 403(1): 154-159
28. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20 tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8 T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18(12): 3281-3292
29. Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65(23): 10794-10800. (Pubitemid 41713347
30. Raber P, Ochoa AC, Rodriguez PC (2012) Metabolism of L-Arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 41(6-7): 614-634
31. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, Costa R, Truini M, Fabbi M, Ferrini S, Barbieri O (2009) IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 125(4): 887-893
32. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ (2012) The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood 120(26): 5188-5198
33. Siebenlist U, Brown K, Claudio E (2005) Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5(6): 435-445. (Pubitemid 40835032
34. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S (2004) Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 10(20): 6821-6829. (Pubitemid 39383030
35. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11): 2584-2589. (Pubitemid 30331967
36. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203(7): 1651-1656. (Pubitemid 44036269
37. Surh YJ, Bode AM, Dong Z (2010) Breaking the NF-kappaB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis. Cancer Prev Res (Phila) 3(11): 1379-1381
38. van Dam M, Mullberg J, Schooltink H, Stoyan T, Brakenhoff JP, Graeve L, Heinrich PC, Rose-John S (1993) Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. J Biol Chem 268(20): 15285-15290. (Pubitemid 23206686
39. Viola A, Sarukhan A, Bronte V, Molon B (2012) The pros and cons of chemokines in tumor immunology. Trends Immunol 33(10): 496-504
40. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, Tsukamoto N, Kudo-Saito C, Fujita T, Sumimoto H, Kawakami Y (2012) Immune suppression and resistance mediated by constitutive activation of Wnt/betacatenin signaling in human melanoma cells. J Immunol 189(5): 2110-2117
41. Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y (2011) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93(3): 294-300
42. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K (2008) Inactivation of NF-kappaB components by covalent binding of (-)- dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 51(18): 5780-5788.